Unmet Needs in Schizophrenia

This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Background on Schizophrenia

Timeline of FDA-Approved Antipsychotics

Comparison of Mechanisms of Action of Current Antipsychotic Agents

Current Antipsychotic Agents What They Can and Cannot Do

Side Effects of Atypical Antipsychotics Shift in Risk Perception

Current Antipsychotic Agents What They Can and Cannot Do

Treatment Effectiveness

Comparative Effectiveness of Current Antipsychotic Agents

What Are Continuing Unmet Needs in Schizophrenia Treatment?

Targets for Novel Drug Development

Summary of Newly Approved and Emerging Antipsychotic Agents

Binding Affinities of Cariprazine for Human Receptors In Vitro and Long-Term Effects on Functioning in Schizophrenia

Binding Affinities of Brexpiprazole for Human Receptors In Vitro and Long-Term Effects on Functioning in Schizophrenia

What Are Continuing Unmet Needs in Schizophrenia Treatment?

Binding Affinities of MIN-101 and Effects on Functioning in Schizophrenia

Evaluating Pimavanserin

Binding Affinities of RP5063 and Effects on Symptoms in Schizophrenia and Schizoaffective Disorder

Binding Affinities and Characteristics of Lumateperone (ITI-007)

Lumateperone Demonstrates Efficacy on PANSS Total Score and Improves Positive Symptoms

Safety Overview Lumateperone

What Are Continuing Unmet Needs in Schizophrenia Treatment?

Summary Points

Abbreviations

Abbreviations (cont)